GlassScriptPhysician profile
Vera Garnett
NPI 1619518206
$3,079.41
in general payments reported to CMS, 2019-2025
24 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,020 · 2023: $327 · 2024: $992 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.30 | 2022-2023 | |
| Boston Scientific Corporation | $363.62 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $225.93 | 2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $211.83 | 2024 | Voquezna |
| Novo Nordisk INC | $193.38 | 2022-2025 | Wegovy |
| Nevro Corp. | $140.68 | 2022 | |
| Neurocrine Biosciences, INC. | $133.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $130.36 | 2023 | Soliris |
| Cequr Corporation | $121.88 | 2025 | Cequr Simplicity |
| Otsuka America Pharmaceutical, INC. | $121.84 | 2025 | Rexulti |
| Amgen INC. | $121.72 | 2025 | Tavneos |
| Actelion Pharmaceuticals US, INC. | $103.91 | 2025 | Opsumit, Uptravi |
| Astellas Pharma US INC | $102.18 | 2024 | Veozah |
| Sanofi Pasteur INC. | $96.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.75 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $83.68 | 2024 | Auvelity |
| Jazz Pharmaceuticals INC. | $82.56 | 2022 | |
| Genzyme Corporation | $81.83 | 2022 | |
| Janssen Pharmaceuticals, INC | $72.35 | 2024 | Spravato |
| Vertex Pharmaceuticals Incorporated | $71.11 | 2025 | |
| Neurelis, INC. | $50.58 | 2024 | Valtoco |
| Vanda Pharmaceuticals INC. | $47.49 | 2024-2025 | Hetlioz, Fanapt |
| Biogen, INC. | $40.42 | 2022 | |
| Lundbeck LLC | $15.29 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vera Garnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.